CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Explore which index funds have the lowest fees for retirement in 2024 and how expense ratios impact long-term growth. This intro explains why fee selection matters.
27,284 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Cloudflare surged about 9% in midday trading after a Scotiabank upgrade. The move comes as AI cloud peers like Oracle...
In the first half of 2026, Vertiv soared as AI data centers pushed demand for cooling and power solutions. This artic...
Investors flocked to Ferroglobe after a midweek earnings update, turning a measured bounce into a genuine momentum pl...
Investing in mobile infrastructure requires understanding the earnings engine behind 5G networks. This guide breaks d...
Li Auto unveiled a $1 billion share repurchase after weaker Q4 deliveries, sending LI higher and triggering a debate ...
Ford shows a weakness in its truck lineup, and GM may push harder to capture share in the high-margin segment. This a...
Three nuclear energy stocks that are quietly gaining traction could redefine portfolios in 2026. Explore Fluor, Urani...
Celsius has moved into the spotlight as a growth play in beverages. This article lays out five practical reasons Cels...
A crypto analyst challenges Ripple’s CEO over Strategy’s BTC funding model as BTC and XRP markets react to evolving f...
Netflix beat revenue but faced a big one-time charge, boosting cash flow guidance. Spotify posted a strong EPS beat b...
A fresh U.S. government win could alter Palantir's growth trajectory and market perception. Here’s what investors sho...